Loading stock data…
Phio Pharmaceuticals Corp (PHIO)
$1.04-0.03 (-2.80%)
Market ClosedLast close Jul 24
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Phio Pharmaceuticals Corp. in the Healthcare sector is trading at $1.04 with a market capitalization of $13M. Wall Street consensus targets $14.00 (1 analysts), implying a +1246.2% move over the next 12 months. The stock is currently near its 52-week low of $0.81, remaining 16.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1246.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.17M↓ | -$2.53M↓ | -$2.50M↓ | -$2.31M↓ | -$1.87M |
| Net Income | -$4.00M↓ | -$2.37M↑ | -$2.39M↓ | -$2.17M↓ | -$1.77M |
Peer Comparison
JNJUNHPFE
Fundamentals
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-66.41%
Volume
Today's trading volume
80,773
Recent News
Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones
Phio Pharmaceuticals has strengthened the intellectual property protection surrounding its INTASYL® gene silencing platform after receiving multiple favorable patent decisions across the United States, Canada, and Japan. Key Investor TakeawaysPhio Pharmaceuticals (NASDAQ:PHIO) received three notices of allowance and one patent grant decision covering its INTASYL® compounds.
BC-Most Active Stocks
CCH Holdings Ltd. 18,962,694 1.32
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
Asian equities traded in the US as American depositary receipts were sharply higher Thursday morning